Solventum Corporation (SOLV) P/E Ratio History
Historical price-to-earnings valuation from 2024 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of February 28, 2026, Solventum Corporation (SOLV) trades at a price-to-earnings ratio of 8.4x, with a stock price of $74.20 and trailing twelve-month earnings per share of $8.88.
The current P/E is 54% below its 5-year average of 18.2x. Over the past five years, SOLV's P/E has ranged from a low of 8.4x to a high of 35.0x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, SOLV trades at a 65% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, SOLV trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SOLV DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Healthcare staffing and facility services peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
SOLVSolventum Corporation | $13B | 8.4 | - | +222% |
HCSGHealthcare Services Group, Inc. | $2B | 26.9 | - | +53% |
CCELCryo-Cell International, Inc. | $27M | 67.4 | - | +104% |
AMSAmerican Shared Hospital Services | $14M | 6.4Lowest | 0.97Best | +246%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $79.24 | $8.88 | 8.9x | -51% |
| FY2025 Q3 | $73.00 | $8.69 | 8.4x | -54% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $75.84 | $2.17 | 34.9x | +92% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $76.04 | $2.17 | 35.0x | +92% |
| FY2024 Q4 | $66.06 | $2.76 | 23.9x | +31% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $69.72 | $4.15 | 16.8x | -8% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $52.88 | $6.12 | 8.6x | -53% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $69.55 | $7.47 | 9.3x | -49% |
Average P/E for displayed period: 18.2x
See SOLV's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SOLV Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare SOLV vs AGIO
See how SOLV stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is SOLV stock overvalued or undervalued?
SOLV trades at 8.4x P/E, below its 5-year average of 18.2x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does SOLV's valuation compare to peers?
Solventum Corporation P/E of 8.4x compares to sector median of 23.7x. The discount suggests lower growth expectations or higher risk.
What is SOLV's PEG ratio?
SOLV PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2024-2025.